These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 28664354)
1. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database. Pageot C; Bezin J; Smith A; Arnaud M; Salvo F; Haramburu F; Bégaud B; Pariente A; Drug Saf; 2017 Nov; 40(11):1099-1107. PubMed ID: 28664354 [TBL] [Abstract][Full Text] [Related]
2. Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Tavassoli N; Lapeyre-Mestre M; Sommet A; Montastruc JL; Br J Clin Pharmacol; 2009 Sep; 68(3):422-6. PubMed ID: 19740400 [TBL] [Abstract][Full Text] [Related]
3. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. Onakpoya IJ; Heneghan CJ; Aronson JK BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061 [TBL] [Abstract][Full Text] [Related]
4. On the clinical evidence leading to tetrazepam withdrawal. Proy-Vega B; Aguirre C; de Groot P; Solís-García del Pozo J; Jordán J Expert Opin Drug Saf; 2014 Jun; 13(6):705-12. PubMed ID: 24845943 [TBL] [Abstract][Full Text] [Related]
5. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Olivier P; Montastruc JL Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082 [TBL] [Abstract][Full Text] [Related]
6. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Mendes D; Alves C; Batel Marques F Expert Opin Drug Saf; 2016 Oct; 15(10):1301-12. PubMed ID: 27467204 [TBL] [Abstract][Full Text] [Related]
7. Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics. Reset A; Skurtveit S; Furu K; Skovlund E Scand J Pain; 2018 Oct; 18(4):667-674. PubMed ID: 30145581 [TBL] [Abstract][Full Text] [Related]
8. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database. Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362 [TBL] [Abstract][Full Text] [Related]
9. Drug Withdrawal Due to Safety: A Review of the Data Supporting Withdrawal Decision. Craveiro NS; Lopes BS; Tomás L; Almeida SF Curr Drug Saf; 2020; 15(1):4-12. PubMed ID: 31584381 [TBL] [Abstract][Full Text] [Related]
10. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Holm L; Ekman E; Jorsäter Blomgren K Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845 [TBL] [Abstract][Full Text] [Related]
11. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Aagaard L; Hallgreen CE; Hansen EH Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924 [TBL] [Abstract][Full Text] [Related]
12. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992 [TBL] [Abstract][Full Text] [Related]
13. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A; Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805 [TBL] [Abstract][Full Text] [Related]
14. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358 [TBL] [Abstract][Full Text] [Related]
15. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D; Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344 [TBL] [Abstract][Full Text] [Related]
17. Drug safety: withdrawn medications are only part of the picture. Rawson NS BMC Med; 2016 Feb; 14():28. PubMed ID: 26873482 [TBL] [Abstract][Full Text] [Related]
18. Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients. Pariente A; Mansiaux Y; Jarné A; Salvo F; Pageot C; Bezin J; Smith A; Bégaud B Eur J Clin Pharmacol; 2017 Dec; 73(12):1655-1663. PubMed ID: 28866826 [TBL] [Abstract][Full Text] [Related]
19. Use of analgesics in France, following dextropropoxyphene withdrawal. Van Ganse E; Belhassen M; Ginoux M; Chrétien E; Cornu C; Ecoffey C; Aubrun F BMC Health Serv Res; 2018 Apr; 18(1):231. PubMed ID: 29609613 [TBL] [Abstract][Full Text] [Related]
20. Drug-induced retroperitoneal fibrosis: a case/non-case study in the French PharmacoVigilance Database. Brasselet D; Chouchana L; Vial T; Damin-Pernik M; Lebrun-Vignes B Expert Opin Drug Saf; 2020 Jul; 19(7):903-914. PubMed ID: 32374194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]